Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AProArt Gene Therapy for ART-SCID
NCT03538899Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- May 2018
- Primary completion
- Jun 2038
- Modality
- Gene Editing, Adoptive Cell Transfer, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of AProArt-CD34 in severe combined immunodeficiency (SCID), sponsored by University of California, San Francisco. Started May 2018; status: recruiting.
02
Drugs
AProArt-CD34
03
Conditions
severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NCT03538899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03538899.